イルケル・ティナイ医師は、アナドル医療センターの泌尿器腫瘍医です。泌尿器腫瘍学会の理事を務めています。ティナイ医師は、低侵襲手術と新膀胱再建術を専門としています。MTQUAによると世界トップ10病院にランクされるアナドルで勤務しており、同センターはジョンズ・ホプキンス・メディシンとも提携しています。
ガルセラン教授は、スペイン有数の腫瘍学センターであるバル・デブロン大学病院の泌尿生殖器腫瘍ユニットを率いています。
メリムスキー教授は、ソラスキー医療センターの腫瘍科を率いており、前立腺がんの高度な治療を専門としています。
Hisar Hospital Intercontinentalにて、腹腔鏡下前立腺全摘除術を含む低侵襲前立腺手術を専門とする。
センテノ医師は32 年の外科的経験を持ち、メイヨークリニックおよびクリーブランドクリニック・フロリダで専門的なトレーニングを受けています。
マルクス・ホイザー教授（医学博士）は泌尿器腫瘍学を専門とし、40本以上の科学論文を発表しています。
Vittawat Ohmpornnuwat医師は腹腔鏡下手術を専門としており、Intrarat病院での前立腺手術において精密さと専門知識を提供しています。
高度な腹腔鏡下手術を含む、包括的な腫瘍治療を専門としています。ヴィオラ・フォックス博士は、BKZゾーリンゲンの血液学・腫瘍学・緩和ケアクリニックを率いています。
オザトリ医師は、イスティニエ・リヴ大学病院にて乳がん、肺がん、消化器がんの治療を専門としています。
アレムダル医師は腫瘍内科を専門とし、アクデニズ大学で高度な研修を受けました。現在はメディカル・パーク・アンタルヤ病院複合施設で診療を行っています。
ニール・クラインマン医師は、シェバ医療センターの結石・内視鏡泌尿器科ユニットを統括しています。複雑な腫瘍に対する腎温存レーザー手術のパイオニアです。フォーブス誌とResultMedにより、2025年および2026年のイスラエルのベストドクターに選出されました。クラインマン医師は、がん治療中に臓器機能を維持するための独自のデュアルレーザーシステムを使用しています。
Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.
1980–1985: Completed doctoral studies at Nagasaki University, Japan
1968–present: Department of Radiology, Chinese PLA General Hospital
1988: Third Prize of the Military Science and Technology Progress Award
1989–present: Member of Radiological Society of North America(RSNA)
1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA
1991: Second Prize of the Military Science and Technology Progress Award
1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology
1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
1993: Granted the Lifetime Special Government Allowance of the State Council
1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology
1994: Third Prize of the Military Science and Technology Progress Award
1997: Second Prize of the Military Science and Technology Progress Award
1997–2009: Standing Member of Chinese Society of Radiology
1999: Third Prize of the Military Science and Technology Progress Award
1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology
2002: Second Prize of the Military Science and Technology Progress Award
2005: Third Prize of the Military Science and Technology Progress Award
Member of Radiological Society of North America(RSNA)
Standing Member of Chinese Society of Radiology
Group Leader of the Group of Intervention of Chinese Journal of Radiology
Deputy Director Member of Chinese Society of Interventional Oncology
Director Member of Beijing Medical Association Society of Interventional Radiology
Deputy Chief Editor of Chinese Journal of Medical Image Technology
Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army
Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology
Awarded the Special Government Allowance of the State Council
Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.
Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”
Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.
In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.
Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.
In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.
Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.
From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.
Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.
1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.
Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.
2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.
Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.
3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.
Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.
4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.
Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.
5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.
Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.
6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.
Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.
7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.
Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.
8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.
Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.
1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.
2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.
3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.
1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.
2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.
3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.
4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.
ウラジーミル・ユトキン医師は、ハダッサ医療センターにおいて30 年以上の専門的な外科手術の経験を有しています。
イルマズ医師は一般外科において豊富な経験を持ち、現在はメディポル大学ペンディク病院に勤務しています。
准教授のジェヴペル・エルソズは、メディポル・アジバデム地区病院にてロボットおよび腹腔鏡下前立腺手術を専門としています。
トゥンカイ・タシュ医師は、イスタンブールのSafe Urologyクリニックの泌尿器科外科医です。P-Shotの応用に関する結果を発表した世界で最初の5人の医師の一人です。タシュ医師は泌尿器腫瘍学と男性の性機能健康を専門としています。ドイツのハイデルベルク大学でフェローシップを修了しました。彼の診療は、再生医療とがんのロボット手術に重点を置いています。
ラマザン・ギョクハン・アティシュ教授は、腹腔鏡およびロボット支援泌尿器科を専門とし、ハイデルベルク大学ハイルブロンクリニックで研修を受けました。
ルカ・カルミニャーニ教授は、ポリクリニコ・サン・ドナート研究病院にて、ロボット支援腹腔鏡手術および前立腺治療を専門とし、1万件以上の手術実績を有しています。
| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 39年の経験 | 進行前立腺がん | バル・デブロン病院泌尿生殖器ユニットの責任者であり、新規治療法に注力。前立腺がんに関する広範な論文を発表しており、スペインのSOGUGグループの共同設立者でもある。 | スペイン | から €615 | |
| #2 | 41年の経験 | 進行した前立腺がんの症例 | イスラエルのトップ病院で腫瘍科を率い、低侵襲技術を専門とする。ESMOおよびASCOのメンバーであり、100以上の出版物がある。 | イスラエル | から $950 | |
| #3 | 20年の経験 | 腹腔鏡下前立腺全摘除術 | MDアンダーソンを含むトップクラスのがん研究所で研修。著名な病院にて前立腺がんに対する低侵襲手術を専門とする。 | トルコ | から $100 | |
| #4 | 32年の経験 | 腹腔鏡下大腸手術 | メイヨークリニックおよびクリーブランドクリニック・フロリダで研修。低侵襲技術を専門とし、ERAS認定による回復プロトコルの強化を行っている。 | スペイン | お問い合わせください | |
| #5 | 31年の経験 | 腹腔鏡下前立腺全摘除術 | 腹腔鏡下手術に重点を置いた泌尿器腫瘍学の専門家。研究実績が高く評価されており、泌尿器科のトップ講師として知られている。 | ドイツ | お問い合わせください | |
| #6 | 26年の経験 | 腹腔鏡下前立腺全摘除術 | Siriraj病院の認定を受けた低侵襲手術のスペシャリスト。腹腔鏡下前立腺手術に精密さと専門的な技術をもたらします。 | タイ | お問い合わせください | |
| #7 | 14年の経験 | 進行性前立腺がんの症例 | 革新的な治療法に重点を置く認定学際的がんセンターを率いています。個別化治療のための遺伝学および分子診断を専門としています。 | ドイツ | お問い合わせください | |
| #8 | 2016年の経験 | 乳がん、肺がん、消化器がん | 複数の腫瘍クリニックでの経験を持つ准教授であり、乳がん、肺がん、消化器がんの治療に注力しています。 | トルコ | お問い合わせください | |
| #9 | 20年の経験 | 前立腺がん治療 | 一流大学で高度な研修を受けた腫瘍内科の認定医。教員としての経験により、最新の治療プロトコルを確実に提供します。 | トルコ | お問い合わせください | |
| #10 | 30年の経験 | 複雑な関節手術 | 名門ヘブライ大学で訓練を受け、20年にわたる外科手術の経験を持つ。複数の言語に堪能で、国際的な患者に効果的な医療を提供できる。 | イスラエル | お問い合わせください |